The US FDA approved four biosimilar drugs in 2021, including the first for ophthalmic use. The total number of biosimilars approved by the US regulator is now 33, although the effects of the pandemic have been felt in the last two years.
A summary of the FDA's work on biosimilars is available in this report from Fish Consulting.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
